In vitro bio-characterization of solid lipid nanoparticles of favipiravir in A549 human lung epithelial cancer cells

Abstract

Objectives: Lung cancer is a leading cause of mortality worldwide. In lung cancer treatment, nebulized solid lipid nanoparticles may be a viable drug delivery method, helping the drug reach sites of action, and improving its inhalation efficiency and pulmonary deposition. This research focused on evaluating the effectiveness of solid lipid nanoparticles of favipiravir (Fav-SLNps) in facilitating drug delivery to sites of action in lung cancer treatment. Methods: The hot-evaporation method was used to formulate Fav-SLNps. The in vitro cell viability, anticancer effects, and cellular uptake activity were evaluated in A549 human lung adenocarcinoma cells treated with the Fav-SLNp formulation. Results: The Fav-SLNps were formulated successfully. Importantly, Fav-SLNps at a concentration of 322.6 mg/ ml were found to be safe and non-toxic toward A549 cells in vitro. The formulation had potential anti-proliferative properties via increasing the proportions of cells in G2/M and G0/G1 phases to 1.20 and 1.13 times those in untreated cells. Additionally, Fav-SLNp treatment significantly induced necrosis in A549 cells. Furthermore, the use of SLNps in the Fav formulation resulted in a macrophage drug uptake 1.23 times that of the free drug. Conclusion: Our results confirmed the internalization and anti-cancer activity of the Fav-SLNp formulation in the A549 lung cancer cell line. Our findings suggest that Fav- SLNps could potentially be used as lung cancer treatment to facilitate drug delivery to sites of action in the lungs